Overview

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Allogene Therapeutics

Treatments:

Cyclophosphamide
Fludarabine